Antibody-drug Conjugate Information | ADCdb

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0ZLBZD
ADC Name	36924655 ADC 5
Synonyms	ADC 5 Click to Show/Hide
Organization	Seoul National University.
Drug Status	Investigative
Drug-to-Antibody Ratio	1.93
Structure
	3D MOL			2D MOL
Antibody Name	Trastuzumab					Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)					Antigen Info
Payload Name	Monomethyl auristatin E					Payload Info
Therapeutic Target	Microtubule (MT)					Target Info
Linker Name	Undisclosed
Conjugate Type	Random conjugation through reduced inter-chain cysteines.

ADC-specific functional property(2027 Update)

Bystander Killing Effect

Click To Hide/Show 1 ADC-specific functional property Data

Bystander Killing Effect	Description	Reference
yes	Bystander killing efficacy of MTX-13 was measured using an in vitro cell culture system with single or cocultures of PTK7- (A549, copy number <1,000/cell) and PTK7+ (H520, copy number >70,000/cell) cell lines (Fig. 2F; Supplementary Fig. S4E-S4G). After 5 days of incubation, cells were sorted for PTK7 expression by flow cytometry (Supplementary Fig. S4F and S4G). MTX-13 killed PTK7-A549 cells efficiently (Fig. 2F; Supplementary Fig. S4F). Negative control ADCs did not induce cell killing compared with untreated wells, confirming the -killing effect of MTX-13. Click to Show/Hide	[1]

References

Ref 1	MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors